Combination of dacarbazine and mitomycin in advanced colorectal cancer.
Twenty evaluable patients with advanced measurable colorectal cancer received 3-week courses of a combination of IV dacarbazine 300 mg/m2/day from day 1 to day 5 and IV mitomycin 2 mg/m2/day from day 1 to day 5. Fourteen of these patients had had no prior chemotherapy and received two or more courses of this two-drug regimen. None of the patients achieved complete or partial response. Severe to life-threatening myelosuppression, was encountered in patients with prior radiotherapy and or prior chemotherapy, and/or in patients with a Karnofsky score less than or equal to 70. Hematologic toxicity was mild in the other patients. Nonhematologic toxic effects were generally mild to moderate and consisted essentially in nausea and vomiting. It is concluded that in our hands the regimen selected for this trial has no significant antitumor activity in advanced colorectal cancer.
D000328:Adult; D000368:Aged; D001855:Bone Marrow Diseases / Q000139:chemically induced; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D003606:Dacarbazine